Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas.

This study investigated quantitated expression of dopamine 2 receptor (D2R) and somatostatin receptors of the five types in a large series of clinically non-functioning pituitary adenomas (CNFAs). Co-expression of these receptors in individual adenomas was studied as well as correlation between receptor types. Adenoma tissue from 198 patients who underwent surgery for CNFAs was analyzed by immunohistochemistry and quantitative real-time PCR. D2R and mRNA was expressed in all 198 adenomas. and were detectable in 85 % and 61 % of adenomas, respectively. Expression of D2R was significantly higher than that of the somatostatin receptors. The median relative expressions were as follows from highest D2R > > > > duanyu1942R5 > High relative expression (ratio to beta-glucuronidase mRNA > 1) of D2R was found in 60 % of tumors, high expression of duanyu1942R1 in 7.5 %, duanyu1942R2 in 7 %, duanyu1942R3 in 4 % and duanyu1942R5 in 0.5 %. The quantity of D2R correlated positively with expression of duanyu1942R2 and and negatively with duanyu1942R1 and Among histological adenoma types, duanyu1942R1 was significantly higher in null-cell adenomas and duanyu1942R3 was lower in silent corticotroph adenomas. In conclusions, in CNFAs, high expression of somatostatin receptors is much less common than that of D2R, and co-expression of both these receptors is exceptional. D2R and duanyu1942R3 seem to be the most promising targets for pharmacological treatment.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}